# GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

> **NCT04590547** · PHASE2 · COMPLETED · sponsor: **GeneOne Life Science, Inc.** · enrollment: 132 (actual)

## Conditions studied

- Pneumonitis
- SARS-CoV Infection

## Interventions

- **DRUG:** GLS-1027
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04590547
- **Lead sponsor:** GeneOne Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-07
- **Primary completion:** 2022-08-14
- **Final completion:** 2023-07-24
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04590547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04590547, "GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04590547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*